 Shares of Horizon Therapeutics are down 50 from last years highs, a consequence of a prolonged biotech market and recent setbacks. The Tepezza growth scare is the main reason the stock is trading at current levels, but Tepezza remains well-positioned for long-term growth with multiple catalysts ahead. 